EU patent court – the countdown also runs for Life Science Companies
The Agreement on a Unified Patent Court (EPC) is expected to enter into force at the beginning of 201920/09/2018
Life Sciences
Loading
Biosimilars and Trademarks Issues
Pharmaceutical products are part of a heavily regulated market20/09/2018 Robert Valenti, DLA Piper, Italy
Medical devices – new self-regulation (Finland)
The importance of self-regulation in medical technology industry increases as the new Finnish Ethical Code includes monetary sanctions20/09/2018 Hanna Paloheimo, Castrén & Snellman, Finland Hilma-Karoliina Markkanen, Castrén & Snellman, Finland
The Brazilian Universal Healthcare System: Limitations on Comprehensive Therapeutic Care
Brazil has an universal healthcare system established by the Federal Constitution, according to which the State must provide all citizens with access to healthcare by devising and putting in place economic and welfare policies targeted at reducing the risk of illnesses of all sorts, while also...20/09/2018 Camila Martino Parise, Pinheiro Neto Advogados, Brazil
New strategies in pharma patent litigation in Russia
It is known that, in the past, permanent injunctions were granted by Russian courts in patent disputes only upon actual commercialisation of the infringing product19/09/2018 Natalia Gulyaeva, Hogan Lovells, Russia
Growing Your Cannabis IP Rights
The cannabis market continues to grow worldwide with medical marijuana currently legal in 35 countries and over 30 US states and counting19/09/2018 Micheline Gravelle, Bereskin & Parr, Canada
The Best and Worst of Times? Pharma Forecast for 2019
For life sciences companies in Canada, these may be the best of times: the end of the “promise doctrine”, supplementary patent protection to compensate for regulatory delays, revamped linkage laws, and robust data protection
{{article.published}}